We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current TCRX market cap is 368.21M. The company's latest EPS is USD -1.8633 and P/E is -4.13.
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 3.36M | 3.1M | 6.8M | 3.15M | 3.89M |
| Operating Income | -16.58M | -18.65M | -22.74M | -24.61M | -24.75M |
| Net Income | -16.25M | -18.72M | -22.56M | -24.05M | -23M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 1.09M | 10.14M | 13.54M | 21.05M |
| Operating Income | -14.21M | -26.23M | -48.64M | -66.64M | -93.46M |
| Net Income | -13.66M | -26.23M | -48.63M | -66.22M | -89.22M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 165.45M | 199.09M | 173.58M | 316.92M | 291.38M |
| Total Liabilities | 48.8M | 99.66M | 95.56M | 126.32M | 122.42M |
| Total Equity | 116.66M | 99.43M | 78.02M | 190.61M | 168.96M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 49.38M | 49.74M | 188.11M | 199.09M | 272.15M |
| Total Liabilities | 6.84M | 32.52M | 27.33M | 99.66M | 121.28M |
| Total Equity | -17.14M | -42.46M | 160.78M | 99.43M | 150.87M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -50.49M | -66.5M | -23.59M | -45.61M | -37.59M |
| Investing | -2.85M | -4.23M | -838k | -1.26M | -62.67M |
| Financing | 29.25M | 29.36M | N/A | 135.68M | 135.42M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -12.52M | -3.02M | -48.68M | -66.5M | -61.36M |
| Investing | -1.25M | -4.24M | -9.94M | -4.23M | -60.76M |
| Financing | 34.81M | 288k | 189.67M | 29.36M | 135.44M |
| Market Cap | 368.21M |
| Price to Earnings Ratio | -4.13 |
| Price to Sales Ratio | 17.49 |
| Price to Cash Ratio | 2.76 |
| Price to Book Ratio | 2.44 |
| Dividend Yield | - |
| Shares Outstanding | 47.88M |
| Average Volume (1 week) | 128.85k |
| Average Volume (1 Month) | 208.69k |
| 52 Week Change | 244.84% |
| 52 Week High | 9.00 |
| 52 Week Low | 1.62 |
| Spread (Intraday) | 5.19 (42.47%) |
| Company Name | TScan Therapeutics Inc |
| Address |
3500 s dupont hwy dover, delaware 19901 |
| Website | https://www.tscan.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
